1. Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy—a porcine model 
D. Fries, T. Haas, A. Klingler, W. Streif, G. Klima, J. Martini, H. Wagner-Berger, P. Innerhofer 
British Journal of Anaesthesia 
Volume 97, Issue 4, Pages (October 2006)
DOI: /bja/ael191
Copyright © 2006 British Journal of Anaesthesia Terms and Conditions

2. Fig 1
Thrombelastograph® tracing showing the dynamics of clot development (clotting time and clot formation time) and clot firmness (maximum clot firmness).
British Journal of Anaesthesia  , DOI: ( /bja/ael191)
Copyright © 2006 British Journal of Anaesthesia Terms and Conditions

3. Fig 2
Clotting time (a), clot formation time (b), alpha angle (c) and maximum clot firmness (d) at baseline (1), after blood withdrawal (2), after colloid administration (3), after substitution of PCC and fibrinogen or saline (4) and at the end of the observation period (5) in the animals treated with placebo (Control) or PCC and fibrinogen concentrate (Treatment). Statistically significant differences between the control group and the treatment group with a P-value <0.05 (*) and <0.003 (**), respectively.
British Journal of Anaesthesia  , DOI: ( /bja/ael191)
Copyright © 2006 British Journal of Anaesthesia Terms and Conditions

4. Fig 3
Electron microscopy scan of a ×3000 magnified blood clot in (a) non-diluted state: dense, branched and meshed reticular fibrin network, (b) blood clot after ∼65% haemodilution with 6% HES 130/0.4: clearly rarefied fibrin network, (c) blood clot after administration of PCC and fibrinogen concentrate to compensate for dilutional coagulopathy: in comparison to (b) the fibrin network is again markedly compact.
British Journal of Anaesthesia  , DOI: ( /bja/ael191)
Copyright © 2006 British Journal of Anaesthesia Terms and Conditions